ClinicalTrials.gg
CompletedNCT06027567IIH:DUALUpdated Feb 27, 2026

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

A Phase 4 interventional study of Semaglutide and Very Low Calorie Diet in Idiopathic Intracranial Hypertension, Intracranial Pressure and Obesity, sponsored by Rigmor Højland Jensen. Completed at 2 sites in Denmark. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Rigmor Højland Jensen · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide for 10 months combined, in the initial 8 weeks following diagnosis, with a Very Low Calorie-Diet (max 800 kcal/day)

Read the detailed description

Idiopathic Intracranial Hypertension is primarily observed in obese female and weight management promotes disease control by yet unsettled mechanisms. Effective, fast and lasting weight loss is crucial, however, hard to achieve. Current weight management strategy in IIH in Denmark is counselling by a dietician. This study investigates whether an initial Very Low Calorie Diet (max 800 kcal/day) for 8 weeks following the diagnosis combined with GLP1-RA treatment throughout 10 months is tolerated and more efficient in achieving substantial weight loss and reduction of intracranial pressure. Furthermore, a number of secondary outcomes are measured including headache burden, quality of life, structure and function of the optic nerve, non-invasive surrogate markers of intracranial pressure, body fat mass, bone health, fatty liver disease and a range of cerebrospinal-, blood- and urine markers of i.a. the hormonal, inflammatory, metabolic, and headache biomarker profile.

The intervention may candidate as a future first-line treatment regime.

02

Conditions studied

  • Idiopathic Intracranial Hypertension
  • Intracranial Pressure
  • Obesity
  • Pseudotumor Cerebri Syndrome
  • Papilledema
  • Weight Loss

Keywords

  • Idiopathic Intracranial Hypertension
  • Papilledema
  • Weight loss
  • Obesity
  • Pseudotumor Cerebri Syndrome
  • Intracranial Pressure
03

In context

Pseudotumor Cerebri

54 studies on the registry are indexed under Pseudotumor Cerebri; 23 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 36 interventional studies indexed under Pseudotumor Cerebri.

Browse Pseudotumor Cerebri studies →

Lead sponsor

Rigmor Højland Jensen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed new onset definite IIH with papilledema and lumbar opening pressure ≥25 cm cerebrospinal fluid according to Friedmann diagnostic criteria
  • ≥ 27
  • Use of methods with failure rates of less than 1 % throughout the study period for group A and for at least an additional 2 months after cessation of Semaglutide
  • Written,

Exclusion criteria

Exclusion Criteria:

  • Unable to provide written or participate
  • Malignant IIH with visual threat that requires surgical intervention, i.e., cerebrospinal fluid diversion (shunting), optic nerve sheet fenestration or cerebral venous sinus stenting
  • Pregnancy or breastfeeding
  • Treatment with antidiabetics, blood-thinners or medication that may increase the risk of adverse events
  • Diabetes, congestive heart failure, severe vascular disease, pancreatitis, severe ophthalmological disorders other than IIH (e.g. retinopathy)
  • History or family history of thyroid carcinomas or Multiple Endocrine Neoplasias (MEN1/MEN2)
  • History of bariatric surgery
  • Known to any contents of Semaglutide®
  • Other severe/uncontrolled mental or physical disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Semaglutide up-titration to 2.4 mg for 10 months initially combined with a Very Low Calorie Diet (800 kcal/day) for 8 weeks. Counselling by dietician Standard medical treatment of intracranial hypertension

    Drug: Semaglutide · Dietary Supplement: Very Low Calorie Diet · Behavioral: Dietician counselling

  • Active comparator
    Standard care (dietician)

    Standard weight loss intervention Counselling by dietician Standard medical treatment of intracranial hypertension

    Behavioral: Dietician counselling

Interventions

  • Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg

    Also known as: Ozempic, Wegovy

  • Dietary supplementVery Low Calorie Diet

    Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products

  • BehavioralDietician counselling

    Counselling by a dietician on weight loss through behavioural changes and life style intervention

06

What researchers measure

Primary outcomes

  1. Weight

    Weight change (%)

    Time frame: 8 weeks

  2. Intracranial pressure

    Change in lumbar opening pressure in cm cerebrospinal fluid measured by manometry

    Time frame: 8 weeks

  3. Intracranial pressure

    Change in lumbar opening pressure (%)

    Time frame: 8 weeks

Secondary outcomes

  1. Weight

    Weight change (%)

    Time frame: 10 months

  2. Intracranial Pressure

    Change in lumbar opening pressure in cm cerebrospinal fluid measured by manometry

    Time frame: 10 months

  3. Intracranial Pressure

    Change in lumbar opening pressure (%)

    Time frame: 10 months

  4. Quality of Life

    Change in total score of Quality of Life (psychological, social, physical, environmental) assessed by the World Health Organization Quality of Life Brief Version Questionnaire (0-100; 0 worst, 100 best)

    Time frame: 8 weeks + 10 months

  5. Headache burden measured by HURT questionnaire

    Change in summation of scores in the questionnaire "Headache Under Response to Treatment Questionnaire" (HURT); 0-24 points were higher numbers are worse outcome

    Time frame: 8 weeks + 10 months

  6. Change in Papilledema

    Change in Frisén Grade (0-5, 0 minimal, 5 worst)

    Time frame: 8 weeks + 10 months

  7. Visual fields

    Perimetric mean deviation (decibel) by Humphrey automated perimetry

    Time frame: 8 weeks + 10 months

  8. EDI-OCT

    Change in Papillary thickness (um) measured by Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT)

    Time frame: 8 weeks + 10 months

  9. Optic disc elevation

    Optic disc elevation (mm) measured by transorbital ultrasonography, (average of 3 scans of each eye with papilledema)

    Time frame: Baseline + 8 weeks + 10 months

  10. Remission

    Proportion of patients with abscence of papilledema with or without intracranial pressure \<25 cm cerebrospinal fluid

    Time frame: 8 weeks + 10 months

  11. Change in fat mass

    Change in body fat percentage measured by Dual Energy X-ray Absorptiometry compared to baseline

    Time frame: 8 weeks + 10 months

  12. Total fat mass

    Body fat percentage measured by Dual Energy X-ray Absorptiometry

    Time frame: Baseline + 8 weeks + 10 months

  13. Feasibility

    Drop-out rate (proportion of patients withdrawing from participation)

    Time frame: 8 weeks + 10 months

  14. Need of intracranial pressure-lowering medication_1

    Dose (mg) of intracranial pressure-lowering medication needed (Acetazolamide, Topiramate, diuretics)

    Time frame: 8 weeks + 10 months

  15. Fatty liver prevalence

    Prevalence of non-alcoholic fatty liver disease evaluated by ultrasonography (subjectively assessed density of liver parenchyma compared to hepatic perivascular density and renal density), assessed by an experienced radiologist with specialization in ultrasonography

    Time frame: Baseline + 8 weeks + 10 months

  16. Monthly headache days

    Number of days with headache for the past 30 days preceding visit

    Time frame: Baseline + 8 weeks + 10 months

  17. Headche severity

    Number of days with mild, moderate, and severy headache, respectively, in the past 30 days preceding visit

    Time frame: Baseline + 8 weeks + 10 months

  18. Headache medication - Acute analgesic use

    Number of days with need of acute analgesic treatment for headache

    Time frame: Baseline + 8 weeks + 10 months

  19. Headache medication - preventive medication

    Need of preventive medical treatment for headache

    Time frame: Baseline + 8 weeks + 10 months

  20. Optic nerve sheath diameter

    Optic nerve sheath diameter (mm) measured by transorbital ultrasonography (average of 3 scans of each eye with papilledema)

    Time frame: Baseline + 8 weeks + 10 months

  21. Peripapillary capillary density

    Change in peripapillary capillary density (ratio of pixels of perpapillary vessels and pixels in the foveal area evaluated by Optic Coherence Tomography Angiography

    Time frame: Baseline + 8 weeks + 10 months

  22. Peripapillary artery-to-venule ratio

    Change in peripapillary artery-to-venule diameter ratio measured by confocal Scanning Laser Ophtalmoscopy

    Time frame: Baseline + 8 weeks + 10 months

  23. Truncal fat

    Change in percentage of truncal adiposity measured by Dual Energy X-ray Absorptiometry

    Time frame: Baseline + 8 weeks + 10 months

  24. Android-gynoid-ratio

    Change in ratio of Android versus gynoid fat percentage using Dual Energy X-ray Absorptiometry

    Time frame: Baseline + 8 weeks and 10 months

  25. Adverse events

    Number of adverse events overall, and sub-categorized into adverse events (AE) (any event happening during attachment to the project) and severe adverse events (SAE) in case of the following conditions: Hospitalization or prolongation of hospitalization, death, life-threatening or significant disability/incapacity

    Time frame: 8 weeks + 10 months

  26. Need of intracranial pressure-lowering medication_2

    Number of patients in need of any intracranial pressure-lowering drug (Acetazolamide, Topiramate, diuretics)

    Time frame: Baseline + 8 weeks + 10 months

  27. Insulin like-Growth-Factor-1

    Level of Insulin like-Growth-Factor-1 in serum (ug/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  28. Insulinlike Growth Factor Binding Protein-3

    Level of Insulinlike Growth Factor Binding Protein-3 in serum (ug/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  29. Growth hormone

    Level of growth hormone in serum ug(L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  30. Lutropin

    Level of Lutropin in serum (IU/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  31. Follitropin

    Level of Follitropin in serum (IU/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  32. Testosteron

    Level of testosteron in serum (nmol/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  33. Estradiol

    Level of estradiol in serum (nmol/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  34. Sex-Hormone Binding Globulin

    Level of Sex-Hormone Binding Globulin in serum (nmol/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  35. Anti-Müllerian Hormone

    Level of Anti-Müllerian Hormone (pmol/L) in serum in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  36. Dehydroepiandrosterone

    Level of Dehydroepiandrosterone (DHEAS) in serum (umol/L) in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  37. Androstenedion

    Level of androstenedion (nmol/L) in serum in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  38. 17-hydroxyprogesterone (mg/d)

    Level of 17-hydroxyprogesterone (mg/d) in serum in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  39. Cortisol 0 min

    Level of cortisol (nmol/L) in serum in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  40. Cortisol 30 min

    Level of cortisol (nmol/L) in serum 30 minutes after stimulation with 0,25 mg SynACHTen in women not taking estrogen-containing contraceptives.

    Time frame: Baseline

  41. Pituitary adenylate cyclase-activating peptide (PACAP) Pituitary adenylate cyclase-activating peptide Pituitary adenylate cyclase-activating peptide

    Level (picograms per milliliter in plasma and cerebrospinal fluid) of Pituitary adenylate cyclase-activating peptide (PACAP)

    Time frame: Baseline + 8 weeks + 10 months

  42. Calcitonin Gene Related Peptide

    Calcitonin Gene Related Peptide (CGRP) level pg/mL (picograms per milliliter in plasma and cerebrospinal fluid)

    Time frame: Baseline + 8 weeks + 10 months

  43. Change in bone marker (CTX)

    Change in carboxy-terminal collagen crosslinks (CTX) level (nanograms per liter)

    Time frame: Baseline + 8 weeks + 10 months

  44. Change in bone marker (PiNP)

    Change in procollagen type I N-propeptide (PiNP) level (micrograms per liter) compared to baseline

    Time frame: baseline + 8 weeks + 10 months

  45. Regional bone density

    Change in regional bone density in grams/square cm (g/cm2) and T- and Z-scores of hip and spine measured by Dual Energy X-ray Absorptiometry compared to baseline

    Time frame: Baseline + 8 weeks + 10 months

  46. Androgen metabolism_1

    Ratio between Etiocholanolone and Androsterone (ng/mg) in 24-hour urine

    Time frame: Baseline + 8 weeks + 10 months

  47. Androgen metabolism_2

    Ratio between 5-alpha-tetrahydrocortisol (5a-THF) and tetrahydrocortisol (THF) in 24-hour urine

    Time frame: Baseline + 8 weeks + 10 months

  48. Androgen metabolism_3

    Level of testosterone in 24-hour urine (ng/L)

    Time frame: Baseline + 8 weeks + 10 months

  49. Androgen metabolism_4

    Level of 3-alpha-androstanediol in 24-hour urine (nmol/L)

    Time frame: Baseline + 8 weeks + 10 months

  50. Androgen metabolism_5

    Level of 11-oxygenated androgens (11-OHA4) (pg/L) in 24-hour urine

    Time frame: Baseline + 8 weeks + 10 months

  51. Intrathecal Semaglutide

    Level of semaglutide in cerebrospinal fluid (picomol/L)

    Time frame: 10 months

  52. Ammoniaemia_1

    Levels of plasma ammonium (umol/L)

    Time frame: Baseline + 8 weeks + 10 months

  53. Ammoniaemia_2

    Correlation between plasma ammonium (umol/L) and presence of fatty liver disease as indicated by liver ultrasonography

    Time frame: Baseline + 8 weeks + 10 months

  54. Ketosis

    Proportion of patients in ketosis measured by urine stix

    Time frame: 8 weeks + 10 months

  55. Change in metabolic parameters

    Change in Homeostatic Model for Insulin Resistance (HOMA2IR) compared to baseline

    Time frame: 8 weeks + 10 months

  56. Change in metabolic parameters

    Change in glycated hemoglobin (mmol/mol) compared to baseline

    Time frame: 8 weeks + 10 months

Other outcomes

  1. Omics

    Metabolomic and proteomic profile, exploratory analyses

    Time frame: Baseline + 8 weeks + 10 months

07

Study locations

2 sites
  • Headache clinic, Department of Neurology, Odense University Hospital
    Odense, Odense 5000, Denmark
  • Danish Headache Center, Department of Neurology, Rigshospitalet
    Glostrup Municipality, 2600, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jan 2025, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Sep 7, 2023
StartActual
Sep 2, 2022
Primary completionActual
Jan 28, 2025
CompletionActual
Oct 28, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06027567
Lead sponsor
Rigmor Højland Jensen
Responsible party
Rigmor Højland Jensen (Professor in Neurology, Danish Headache Center) — Sponsor-investigator
First posted
Sep 7, 2023
Start date
Sep 2, 2022
Primary completion
Jan 28, 2025
Completion
Oct 28, 2025
Last update
Feb 27, 2026

Study contacts

Rigmor H Jensen, Professor
study director · Danish Headache Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion